A Comprehensive Review of Pediatric Obesity: Causes, Consequences, and Multicomponent Treatment Approaches
More details
Hide details
1
Dr. Anna Gostyńska Wolski Hospital, Warsaw, Poland
2
Warsaw Southern Hospital, Warsaw, Poland
3
Praski Hospital of the Transfiguration of Our Lord, Warsaw, Poland
KEYWORDS
TOPICS
ABSTRACT
Pediatric obesity has emerged as one of the most pressing public health challenges of the 21st century, with significant implications for both physical and psychological well-being. This review synthesizes current evidence on the multifactorial causes, health consequences, and management strategies for childhood and adolescent obesity. The development of obesity in early life is shaped by complex interactions among genetic, epigenetic, environmental, behavioral, and socioeconomic factors. Key contributors include poor dietary habits, sedentary lifestyle, maternal and prenatal influences, and psychosocial determinants. The consequences of pediatric obesity extend far beyond excess adiposity, encompassing cardiometabolic disorders, orthopedic problems, respiratory dysfunction, and psychosocial impairments. Effective management requires an individualized, multidisciplinary, and family-centered approach. Evidence supports multicomponent interventions that integrate dietary modification, increased physical activity, behavioral and psychological support, and—in selected cases—pharmacological or surgical treatment. Pharmacotherapy with glucagon-like peptide-1 receptor agonists, such as liraglutide and semaglutide, has shown promising results in adolescents with severe obesity, while bariatric surgery remains a viable option for refractory cases. Emerging personalized, pathophysiology-informed strategies and novel pharmacologic agents offer new opportunities for targeted intervention. Addressing pediatric obesity necessitates long-term, comprehensive, and sustainable efforts that engage healthcare systems, families, and communities to mitigate the escalating burden of this condition.
REFERENCES (19)
1.
Taghizadeh S, Farhangi MA. The effectiveness of pediatric obesity prevention policies: a comprehensive systematic review and dose-response meta-analysis of controlled clinical trials. J Transl Med. 2020;18(1):480. doi: 10.1186/s12967-020-02640-1.
2.
Jebeile H, Kelly AS, O’Malley G, Baur LA. Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol. 2022;10(5):351–365. doi: 10.1016/S2213-8587(22)00047-X.
3.
Nogueira-de-Almeida CA, Weffort VRS, Ued FDV, Ferraz IS, Contini AA, Martinez EZ, et al. What causes obesity in children and adolescents? J Pediatr (Rio J). 2024;100(Suppl 1):S48–S56. doi: 10.1016/j.jped.2023.09.011.
4.
Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. doi: 10.1056/NEJMoa1614362.
10.
Dzielska A, Woynarowska M. Psychosocial predictors of body weight congruence in adolescents aged 15 and 17 years in Poland: Findings from the Health Behaviour in School-aged Children (HBSC) study. Int J Environ Res Public Health. 2022;19(4):2342. doi: 10.3390/ijerph19042342.
11.
La Fauci G, Montalti M, Di Valerio Z, Gori D, Salomoni MG, Salussolia A, et al. Obesity and COVID-19 in Children and Adolescents: Reciprocal Detrimental Influence–Systematic Literature Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(13):7603. doi: 10.3390/ijerph19137603.
12.
Ball GDC, Merdad R, Birken CS, Cohen TR, Goodman B, Hadjiyannakis S, et al. Managing obesity in children: a clinical practice guideline. CMAJ 2025;197(14):E372–E389. doi: 10.1503/cmaj.241456.
13.
Fournier E, Moore H, Alghamdi ZS, Thivel D. Low-Carbohydrate Diets for the Management of Pediatric Obesity: A Systematic Review and Meta-analysis. Nutr Rev. 2026;84(2):267–303. doi: 10.1093/nutrit/nuaf029.
14.
Lister NB, Baur LA, Felix JF, Hill AJ, Marcus C, Reinehr T, et al. Child and adolescent obesity. Nat Rev Dis Primers. 2023;9(1):24. doi: 10.1038/s41572-023-00435-4.
15.
Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H, et al. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. Pharmaceuticals. 2024;17(7):828. doi: 10.3390/ph17070828.
16.
Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC, et al. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. J Pediatr. 2017;181:146–153.e3. doi: 10.1016/j.jpeds.2016.10.076.
17.
Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245–2257. doi: 10.1056/NEJMoa2208601.
18.
Kelly AS, Armstrong SC, Michalsky MP, Fox CK. Obesity in Adolescents: A Review. JAMA 2024;332(9):738–748. doi: 10.1001/jama.2024.11809.
19.
Torbahn G, Lischka J, Brown T, Ells LJ, Kelly AS, Wabitsch M, et al. Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps. Clin Endocrinol (Oxf). 2025;102(1):51–61. doi: 10.1111/cen.15133.